Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Gram-positive Cell Wall Synthesis01:23

Inhibitors of Gram-positive Cell Wall Synthesis

84
Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
84
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

34
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within...
34
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

107
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and...
107
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

1.9K
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
1.9K
Bacterial Toxins01:12

Bacterial Toxins

51
Bacterial toxins are sophisticated virulence factors that enable pathogenic bacteria to interact with, invade, and damage host tissues. These toxins fall broadly into two types: protein exotoxins, which are secreted into the environment and target specific host receptors, and lipopolysaccharide endotoxins, which are structural components of the bacterial outer membrane released primarily during bacterial lysis or membrane shedding. Exotoxins generally act more selectively, binding to cell...
51
Antimicrobial Proteins01:23

Antimicrobial Proteins

15.4K
Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
15.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment strategies for imipenemase-producing Gram-negative infections: lessons from Japan.

The Lancet. Microbe·2026
Same author

Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance.

The Lancet. Infectious diseases·2026
Same author

Evaluating the antibacterial activity of ceftazidime/avibactam and aztreonam combinations against multidrug-resistant Stenotrophomonas maltophilia complex isolates in a hollow fibre infection model.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same author

Exploring the activity of a novel orally bioavailable β-lactam-β-lactamase inhibitor combination, ceftibuten-ledaborbactam, against Enterobacterales-carrying <i>bla</i><sub>OXA-48</sub>.

Microbiology spectrum·2025
Same author

<i>Burkholderia pseudomallei</i> PenI β-lactamase and variants are potently inhibited by taniborbactam.

Antimicrobial agents and chemotherapy·2025
Same author

Cefiderocol "under siege"? Understanding the rise of NDM-mediated resistance to novel agents.

Chemical science·2025

Related Experiment Video

Updated: Apr 1, 2026

The Use of a &#946;-lactamase-based Conductimetric Biosensor Assay to Detect Biomolecular Interactions
08:06

The Use of a β-lactamase-based Conductimetric Biosensor Assay to Detect Biomolecular Interactions

Published on: February 1, 2018

9.7K

B1-Metallo-β-Lactamases: Where Do We Stand?

Maria F Mojica, Robert A Bonomo1, Walter Fast2

  • 1Medical Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, 10701 East Blvd., Cleveland, OH 44106, USA. robert.bonomo@va.gov.

Current Drug Targets
|October 2, 2015
PubMed
Summary

Metallo-β-lactamases (MBLs) are enzymes that inactivate crucial antibiotics. This review details class B1 MBLs, like NDM-1, IMP-1, and VIM-2, and their structural features to guide the development of new inhibitors.

More Related Videos

Isolation and Identification of Waterborne Antibiotic-Resistant Bacteria and Molecular Characterization of their Antibiotic Resistance Genes
08:58

Isolation and Identification of Waterborne Antibiotic-Resistant Bacteria and Molecular Characterization of their Antibiotic Resistance Genes

Published on: March 3, 2023

8.4K
Anti-virulent Disruption of Pathogenic Biofilms using Engineered Quorum-quenching Lactonases
07:47

Anti-virulent Disruption of Pathogenic Biofilms using Engineered Quorum-quenching Lactonases

Published on: January 1, 2016

12.2K

Related Experiment Videos

Last Updated: Apr 1, 2026

The Use of a &#946;-lactamase-based Conductimetric Biosensor Assay to Detect Biomolecular Interactions
08:06

The Use of a β-lactamase-based Conductimetric Biosensor Assay to Detect Biomolecular Interactions

Published on: February 1, 2018

9.7K
Isolation and Identification of Waterborne Antibiotic-Resistant Bacteria and Molecular Characterization of their Antibiotic Resistance Genes
08:58

Isolation and Identification of Waterborne Antibiotic-Resistant Bacteria and Molecular Characterization of their Antibiotic Resistance Genes

Published on: March 3, 2023

8.4K
Anti-virulent Disruption of Pathogenic Biofilms using Engineered Quorum-quenching Lactonases
07:47

Anti-virulent Disruption of Pathogenic Biofilms using Engineered Quorum-quenching Lactonases

Published on: January 1, 2016

12.2K

Area of Science:

  • Microbiology
  • Structural Biology
  • Drug Discovery

Background:

  • Metallo-β-lactamases (MBLs) are critical enzymes conferring resistance to β-lactam antibiotics.
  • MBLs belong to the metallo-hydrolase superfamily, characterized by a conserved αβ/βα fold and zinc-dependent activity.
  • Class B1 MBLs, including NDM-1, IMP-1, and VIM-2, are of significant clinical concern due to their broad substrate spectrum.

Purpose of the Study:

  • To review the molecular epidemiology of clinically significant class B1 MBLs.
  • To discuss structural studies of prominent B1 MBLs (NDM-1, IMP-1, VIM-2).
  • To explore implications of structural and mechanistic diversity for the design of novel MBL inhibitors.

Main Methods:

  • Literature review of molecular epidemiology data.
  • Analysis of published structural studies on NDM-1, IMP-1, and VIM-2.
  • Comparative analysis of active site architectures and catalytic mechanisms.

Main Results:

  • Class B1 MBLs exhibit diverse active site configurations and zinc coordination, complicating inhibitor development.
  • Specific examples like NDM-1, IMP-1, and VIM-2 highlight the challenges posed by these enzymes.
  • Understanding these structural differences is key to designing effective inhibitors.

Conclusions:

  • The structural and mechanistic heterogeneity of class B1 MBLs presents a significant hurdle for developing broad-spectrum inhibitors.
  • Targeted inhibitor design strategies are needed to address the growing threat of MBL-producing bacteria.
  • Further research into MBL structure-activity relationships is crucial for combating antibiotic resistance.